Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (LBL)
This randomised, double-blind, placebo-controlled crossover trial (n=20) conducted by the University Hospital in Basel, Switzerland, aims to investigate the effects of ketanserin, olanzapine, and lorazepam administered after LSD (150µg) on the acute response to LSD in healthy subjects.
Details
Randomised, quadruple‑blind crossover in healthy volunteers comparing single doses of LSD 150 µg with post‑LSD administration of ketanserin 40 mg, olanzapine 10 mg, lorazepam 2 mg, or placebo to assess attenuation and shortening of the acute LSD response.
The study examines pharmacological interventions as emergency or mitigation strategies for acute psychedelic distress and to probe the role of ongoing 5‑HT2A receptor stimulation in mediating subjective effects.
Outcomes include duration and intensity of subjective drug effects, changes in quality of experience, sensorimotor gating, sleep measures and safety/tolerability.